CAR T-Cell Utility in Hematologic Cancers: Alex Herrera, MD

The hematologist and oncologist from City of Hope discussed the utility of CAR T cells in patients with hematologic cancers.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Alex Herrera, MD, hematologist/oncologist, and assistant professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, about the utility of CAR T cell therapy in hematologic cancers.

Herrera discussed how thus farm autologous CAR T cells have demonstrated a robust and durable antitumor response in a sizable minority of patients. Additionally, allogeneic, or off-the-shelf CAR T cells are being studied in clinical trials to examine how they compare with CD19-directed treatments.

Looking forward, there is still more to be learned about the durability of CAR T-cell therapy in patients, and how that correlates with the robustness of the antitumor response, Herrera continues. Allogeneic CAR T cells represent a potential option for patients who are unable to wait for the production of autologous CAR T cells; however, more efforts are underway to further optimize this treatment, Herrera concludes.

Related Videos
Angela Genge, MD, FRCPC, eMBA, on Targeting STMN2 to Rescue Neurons in ALS
Peter Marks, MD, PhD
Jeffrey S. Chamberlain, PhD
Amer Beitinjaneh, MD, MSc, MPH, FACP, on Treating EBV+ PTLD With Tab-cel
Marco Davila, MD, PhD, on Investigating Mechanisms of CAR T Resistance in B-cell Malignancies
Chiraag Kapadia on Investigating Clonal Hematopoiesis After CAR T-cell Therapy
© 2023 MJH Life Sciences

All rights reserved.